Measuring the unmeasurable: automated bone scan index as a quantitative endpoint in prostate cancer clinical trials.

Jose Mauricio Mota Andrew J ArmstrongSteven M LarsonJosef J FoxMichael J Morris

Published in: Prostate cancer and prostatic diseases (2019)

aBSI provides a quantitative measurement that is feasible, reproducible, and in analyses to date correlates with OS and symptomatic progression. These findings support the aBSI to risk-stratify men with mCRPC for clinical trial enrollment. Future studies quantifying aBSI change over time as an intermediate endpoint for evaluating new systemic therapies are needed.

Keyphrases

clinical trial
prostate cancer
phase ii
high resolution
computed tomography
open label
machine learning
bone mineral density
double blind
study protocol
deep learning
high throughput
current status
magnetic resonance imaging
mass spectrometry
middle aged
postmenopausal women
single cell